Illumina, Inc. (NASDAQ:ILMN) Receives $165.63 Consensus PT from Brokerages

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty analysts that are presently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $165.63.

A number of equities analysts have issued reports on the company. Hsbc Global Res raised Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Barclays raised their target price on Illumina from $135.00 to $145.00 and gave the company an "equal weight" rating in a research note on Tuesday, November 5th. Robert W. Baird lifted their price target on shares of Illumina from $124.00 to $139.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Morgan Stanley cut their price objective on Illumina from $156.00 to $150.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Citigroup cut Illumina from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th.

Illumina Stock Performance

ILMN stock traded down $0.70 during mid-day trading on Monday, reaching $136.67. The company had a trading volume of 1,247,185 shares, compared to its average volume of 1,836,016. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock's 50-day simple moving average is $139.60 and its two-hundred day simple moving average is $133.77. The stock has a market capitalization of $21.68 billion, a P/E ratio of -13.72 and a beta of 1.11. Illumina has a one year low of $100.08 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS. Research analysts anticipate that Illumina will post 4.11 EPS for the current year.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently modified their holdings of the business. Versant Capital Management Inc raised its holdings in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after purchasing an additional 141 shares during the period. Massmutual Trust Co. FSB ADV lifted its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after buying an additional 168 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock worth $62,000 after buying an additional 212 shares during the period. Finally, Focused Wealth Management Inc acquired a new position in Illumina in the 3rd quarter valued at $63,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.